Mark Dilworth

Medicine & Life Sciences

1. Methylation 100%
2. Barrett Esophagus 90%
3. Epigenomics 68%
4. Ulcerative Colitis 59%
5. Neoplasms 57%
6. Biomarkers 55%
7. Adenocarcinoma 55%
8. Systematic Reviews 54%
9. Colorectal Neoplasms 47%
10. Mutation 45%
11. Retroperitoneal liposarcoma 41%
12. Whole Genome Sequencing 38%
13. High-Throughput Nucleotide Sequencing 36%
14. Colitis 36%
15. Liposarcoma 31%
16. Genome 31%
17. Tumor Burden 29%
18. Chemoradiotherapy 26%
19. Gene Expression Profiling 25%
20. Rectal Neoplasms 25%
21. Genetic Promoter Regions 24%
22. Disease-Free Survival 23%
23. Phosphatidylinositol 3-Kinases 20%
24. Emergencies 19%
25. Mucous Membrane 17%
26. Technology 17%
27. Gene Fusion 16%
28. Hemorrhage 16%
29. Biopsy 14%
30. Colonoscopy 13%
31. Epigenome 12%
32. Therapeutics 12%
33. DNA Repair 12%
34. Genes 11%
35. Laparotomy 11%
36. DNA 11%
37. Chromosomes, Human, Pair 12 11%
38. Chromosomes, Human, Pair 6 10%
39. Drug Therapy 10%
40. Breast Neoplasms 10%
41. Datasets 10%
42. Ireland 9%
43. RNA Sequence Analysis 9%
44. Metabolomics 9%
45. Human Genome 8%
46. APC Genes 8%
47. Genetic Predisposition to Disease 8%
48. Area Under Curve 8%
49. Elderly 8%
50. Disease Management 8%